{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:26:44Z","timestamp":1793921204051,"version":"4.8.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jaad.2021.12.065","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T02:20:50Z","timestamp":1644632450000},"page":"291-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation"],"prefix":"10.1016","volume":"88","author":[{"given":"Dayoung","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ozog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem F.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5507\/bp.2006.003","article-title":"Ultraviolet light induced alteration to the skin","volume":"150","author":"Svobodova","year":"2006","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/jid.2010.95","article-title":"Impact of long-wavelength UVA and visible light on melanocompetent skin","volume":"130","author":"Mahmoud","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/php.13143","article-title":"Impact of long-wavelength ultraviolet A1 and visible light on light-skinned individuals","volume":"95","author":"Kohli","year":"2019","journal-title":"Photochem Photobiol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11536930-000000000-00000","article-title":"Postinflammatory hyperpigmentation: etiologic and therapeutic considerations","volume":"12","author":"Callender","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/bjd.15940","article-title":"Synergistic effects of long-wavelength ultraviolet A1 and visible light on pigmentation and erythema","volume":"178","author":"Kohli","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/pcmr.12692","article-title":"Development and validation of a reproducible model for studying post-inflammatory hyperpigmentation","volume":"31","author":"Passeron","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jaad.2020.04.079","article-title":"Photoprotection beyond ultraviolet radiation: a review of tinted sunscreens","volume":"84","author":"Lyons","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/phpp.12086","article-title":"Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial","volume":"30","author":"Castanedo-Cazares","year":"2014","journal-title":"PhotodermatolPhotoimmunol Photomed"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.065_bib9","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/jdv.12332","article-title":"The use of sunscreen starting on the first day after ablative fractional skin resurfacing","volume":"28","author":"Wanitphakdeedecha","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib10","doi-asserted-by":"crossref","first-page":"AB215","DOI":"10.1016\/j.jaad.2015.02.871","article-title":"Evaluation and effectiveness of a photoprotection composition (sunscreen) on subjects of skin of color","volume":"72","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1468-3083.2007.02185.x","article-title":"Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women","volume":"21","author":"Lakhdar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2021.12.065_bib12","first-page":"15","article-title":"Les signes dermatologiques physiologiques de la grossesse","volume":"126","author":"Khadir","year":"1999","journal-title":"Ann Dermatol Venerol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1396-0296.2004.04015.x","article-title":"Management of dyschromias in ethnic skin","volume":"17","author":"Halder","year":"2004","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-4165(91)90186-K","article-title":"Mechanism of inhibition of melanogenesis by hydroquinone","volume":"1073","author":"Palumbo","year":"1991","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.065_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archderm.1995.01690240119022","article-title":"Melasma. Etiologic and therapeutic considerations","volume":"131","author":"Grimes","year":"1995","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1529-8019.2006.00085.x","article-title":"Retinoid therapy of pigmentary disorders","volume":"19","author":"Ortonne","year":"2006","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40257-016-0239-8","article-title":"Facial hyperpigmentation in skin of color: special considerations and treatment","volume":"18","author":"Vashi","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2021.12.065_bib18","doi-asserted-by":"crossref","first-page":"952452","DOI":"10.1155\/2012\/952452","article-title":"Depigmenting effect of Kojic acid esters in hyperpigmented B16F1 melanoma cells","volume":"2012","author":"Lajis","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s12272-011-0515-3","article-title":"Inhibition of UVA-mediated melanogenesis by ascorbic acid through modulation of antioxidant defense and nitric oxide system","volume":"34","author":"Panich","year":"2011","journal-title":"Arch Pharm Res"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib20","first-page":"20","article-title":"Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color","volume":"3","author":"Davis","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/2229-5178.110593","article-title":"Vitamin C in dermatology","volume":"4","author":"Telang","year":"2013","journal-title":"Indian Dermatol Online J"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2133.1992.tb00122.x","article-title":"Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage","volume":"127","author":"Darr","year":"1992","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2133.2002.04834.x","article-title":"The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer","volume":"147","author":"Hakozaki","year":"2002","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1346-8138.2008.00522.x","article-title":"Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study","volume":"35","author":"Ertam","year":"2008","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ics.12117","article-title":"Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti-aging effects","volume":"36","author":"Chaudhuri","year":"2014","journal-title":"Int J Cosmet Sci"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib26","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1271\/bbb.100221","article-title":"Inhibitory effects of bakuchiol, bavachin, and isobavachalcone isolated from Piper longum on melanin production in B16 mouse melanoma cells","volume":"74","author":"Ohno","year":"2010","journal-title":"BiosciBiotechnol Biochem"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib27","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jid.2018.01.019","article-title":"Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase","volume":"138","author":"Mann","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib28","first-page":"E7","article-title":"Treatment of melasma using tranexamic acid: what\u2019s known and what\u2019s next","volume":"101","author":"Sheu","year":"2018","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jocd.12026","article-title":"Tranexamic acid: an important adjuvant in the treatment of melasma","volume":"12","author":"Tse","year":"2013","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib30","first-page":"299","article-title":"Inhibition of tumour vascularization by tranexamic acid. Experimental studies on possible mechanisms","volume":"1","author":"Sundbeck","year":"1981","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.13424","article-title":"Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4103\/ijdvl.IJDVL_209_17","article-title":"Chemical leukoderma due to hydroquinone: an unusual phenomenon","volume":"85","author":"Das","year":"2019","journal-title":"Indian J DermatolVenereol Leprol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/01.DER.0000438425.56740.8a","article-title":"Hydroquinone-induced depigmentation: case report and review of the literature","volume":"25","author":"Jow","year":"2014","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2021.12.065_bib34","series-title":"Hydroquinone","author":"Schwartz","year":"2021"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1346-8138.1998.tb02463.x","article-title":"Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies","volume":"25","author":"Kang","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2021.12.065_bib36","doi-asserted-by":"crossref","first-page":"379173","DOI":"10.1155\/2011\/379173","article-title":"A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma","volume":"2011","author":"Navarrete-Sol\u00eds","year":"2011","journal-title":"Dermatol Res Pract"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib37","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/jocd.12744","article-title":"Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma","volume":"18","author":"Taghavi","year":"2019","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-4362.2003.01621.x","article-title":"A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma","volume":"42","author":"Haddad","year":"2003","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-4632.2004.02134.x","article-title":"A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma","volume":"43","author":"Espinal-Perez","year":"2004","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546630050517333","article-title":"A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma","volume":"11","author":"Ennes","year":"2000","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib41","first-page":"697","article-title":"A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma","volume":"159","author":"Chan","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1468-3083.2011.04135.x","article-title":"Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity","volume":"26","author":"Arellano","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib43","first-page":"67","article-title":"Efficacy and safety of a new triple-combination agent for the treatment of facial melasma","volume":"72","author":"Taylor","year":"2003","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archderm.1975.01630130042004","article-title":"A new formula for depigmenting human skin","volume":"111","author":"Kligman","year":"1975","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2009.06.067","article-title":"Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma","volume":"62","author":"Grimes","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib46","first-page":"57","article-title":"Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma","volume":"75","author":"Torok","year":"2005","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1473-2165.2011.00580.x","article-title":"Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma","volume":"10","author":"Farshi","year":"2011","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib48","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0149-2918(98)80077-5","article-title":"Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone","volume":"20","author":"Kakita","year":"1998","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib49","first-page":"586","article-title":"Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study","volume":"10","author":"Kircik","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib50","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1524-4725.1996.tb00345.x","article-title":"The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions","volume":"22","author":"Garcia","year":"1996","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/0019-5154.108070","article-title":"A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma","volume":"58","author":"Monteiro","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib52","first-page":"153","article-title":"Evaluation of a kojic acid, Emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening","volume":"86","author":"Draelos","year":"2010","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1524-4725.1999.08236.x","article-title":"Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid","volume":"25","author":"Lim","year":"1999","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2310\/7750.2008.07092","article-title":"Clinical efficacy of 25% L-ascorbic acid (C\u2019ensil) in the treatment of melasma","volume":"13","author":"Hwang","year":"2009","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib55","first-page":"476","article-title":"An open label clinical trial to evaluate the efficacy and tolerance of a retinol and vitamin C facial regimen in women with mild-to-moderate hyperpigmentation and photodamaged facial skin","volume":"15","author":"Herndon","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib56","first-page":"WC08","article-title":"Clinical efficacy and safety on combining 20% trichloroacetic acid peel with topical 5% ascorbic acid for melasma","volume":"11","author":"Dayal","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1473-2165.2007.00302.x","article-title":"Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study","volume":"6","author":"Soliman","year":"2007","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jocd.12006","article-title":"Stability, transdermal penetration, and cutaneous effects of ascorbic acid and its derivatives","volume":"11","author":"Stamford","year":"2012","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000069943","article-title":"A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma","volume":"206","author":"Huh","year":"2003","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib60","first-page":"45","article-title":"Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic\/malic acid skin care regimen","volume":"12","author":"Taylor","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/jidsymp.2008.8","article-title":"The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders","volume":"13","author":"Zhu","year":"2008","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1467-2494.2004.00228.x","article-title":"Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin","volume":"26","author":"Bissett","year":"2004","journal-title":"Int J Cosmet Sci"},{"key":"10.1016\/j.jaad.2021.12.065_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CCID.S39246","article-title":"Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study","volume":"6","author":"Castanedo-Cazares","year":"2013","journal-title":"ClinCosmet Investig Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib64","first-page":"863","article-title":"Efficacy and tolerability of a skin brightening\/anti-aging cosmeceutical containing retinol 0.5%, niacinamide, hexylresorcinol, and resveratrol","volume":"15","author":"Farris","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/14764172.2010.487910","article-title":"Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: a prospective study","volume":"12","author":"Polnikorn","year":"2010","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.jaad.2021.12.065_bib66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13104-016-2047-x","article-title":"Arbutin encapsulated micelles improved transdermal delivery and suppression of cellular melanin production","volume":"9","author":"Liang","year":"2016","journal-title":"BMC Res Notes"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib67","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0040-4020(73)80071-7","article-title":"Psoralea corylifolia Linn.\u20141. bakuchiol, a novel monoterpene phenol","volume":"29","author":"Mehta","year":"1973","journal-title":"Tetrahedron"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bjd.16918","article-title":"Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing","volume":"180","author":"Dhaliwal","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.065_bib69","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00403-020-02071-4","article-title":"Trichloroacetic acid model to accurately capture the efficacy of treatments for postinflammatory hyperpigmentation","volume":"312","author":"Lyons","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib70","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jocd.13615","article-title":"Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation","volume":"20","author":"Vachiramon","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib71","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/jdv.17344","article-title":"Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial","volume":"35","author":"Lima","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib72","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jid.2019.02.013","article-title":"Effective tyrosinase inhibition by Thiamidol results in significant improvement of mild to moderate melasma","volume":"139","author":"Arrowitz","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ics.12626","article-title":"Thiamidol containing treatment regimens in facial hyperpigmentation: an international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study","volume":"42","author":"Philipp-Dormston","year":"2020","journal-title":"Int J Cosmet Sci"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ics.12694","article-title":"Effective reduction of post-inflammatory hyperpigmentation with the tyrosinase inhibitor isobutylamido-thiazolyl-resorcinol (Thiamidol)","volume":"43","author":"Roggenkamp","year":"2021","journal-title":"Int J Cosmet Sci"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib75","first-page":"454","article-title":"Effect of a tranexamic acid, kojic acid, and niacinamide containing serum on facial dyschromia: A clinical evaluation","volume":"18","author":"Desai","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/srt.12107","article-title":"Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial","volume":"20","author":"Lee","year":"2014","journal-title":"Skin Res Technol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib77","first-page":"753","article-title":"Topical tranexamic acid as a promising treatment for melasma","volume":"19","author":"Ebrahimi","year":"2014","journal-title":"J Res Med Sci"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib78","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/14764172.2012.685478","article-title":"Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial","volume":"14","author":"Kanechorn Na Ayuthaya","year":"2012","journal-title":"J Cosmet Laser Ther"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib79","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/09546634.2017.1351608","article-title":"Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study","volume":"29","author":"Farshi","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.065_bib80","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/ijd.15146","article-title":"A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women","volume":"59","author":"Lima","year":"2020","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib81","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/ajd.13432","article-title":"Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: a randomised, double-blinded trial","volume":"62","author":"Nguyen","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib82","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jocd.12837","article-title":"Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman\u2019s formula","volume":"18","author":"Kasraee","year":"2019","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jocd.13755","article-title":"A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids)","volume":"20","author":"Mathe","year":"2021","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib84","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis","volume":"75","author":"Lee","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib85","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/ajd.12474","article-title":"Oral tranexamic acid lightens refractory melasma","volume":"58","author":"Tan","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib86","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2017.09.053","article-title":"Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma","volume":"78","author":"Del Rosario","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib87","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2340\/00015555-2668","article-title":"Efficacy and safety of tranexamic acid in melasma: A meta-analysis and systematic review","volume":"97","author":"Kim","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2021.12.065_bib88","doi-asserted-by":"crossref","first-page":"1683414","DOI":"10.1155\/2018\/1683414","article-title":"Tranexamic acid for adults with melasma: A systematic review and meta-analysis","volume":"2018","author":"Zhang","year":"2018","journal-title":"BioMed Res Int"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib89","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","article-title":"Treatment of melasma with oral administration of tranexamic acid","volume":"36","author":"Wu","year":"2012","journal-title":"Aesthetic Plast Surg"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib90","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/jdv.12209","article-title":"Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial","volume":"28","author":"Li","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib91","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: a clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib92","doi-asserted-by":"crossref","first-page":"344","DOI":"10.36849\/JDD.5622","article-title":"The use of tranexamic acid to prevent and treat post-inflammatory hyperpigmentation","volume":"20","author":"Lindgren","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib93","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/09546634.2011.643220","article-title":"Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser","volume":"24","author":"Cho","year":"2013","journal-title":"J Dermatolog Treat"},{"issue":"3 pt 1","key":"10.1016\/j.jaad.2021.12.065_bib94","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/dsu.12060","article-title":"Oral tranexamic acid enhances the efficacy of low-fluence 1064-Nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in koreans: a randomized, prospective trial","volume":"39","author":"Shin","year":"2013","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib95","article-title":"Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial","volume":"60","author":"Padhi","year":"2015","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3126\/kumj.v10i4.10993","article-title":"Oral tranexamic acid for the treatment of melasma","volume":"10","author":"Karn","year":"2021","journal-title":"Kathmandu Univ Med J"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib97","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40257-017-0263-3","article-title":"Tranexamic acid in the treatment of melasma: a review of the literature","volume":"18","author":"Perper","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib98","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/ijd.13293","article-title":"Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study","volume":"55","author":"Muthu","year":"2016","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib99","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jdcr.2020.06.037","article-title":"A case of recalcitrant lichen planus pigmentosus treated by oral isotretinoin","volume":"6","author":"Shah","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jdcr.2019.12.015","article-title":"Combination therapy with prednisone and isotretinoin in early erythema dyschromicum perstans: a retrospective series","volume":"6","author":"Diaz","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib101","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jaad.2004.06.027","article-title":"Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin","volume":"51","author":"Middelkamp-Hup","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib102","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/ijms17071026","article-title":"Fernblock (polypodium leucotomos extract): molecular mechanisms and pleiotropic effects in light-related skin conditions, photoaging and skin cancers, a review","volume":"17","author":"Parrado","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib103","first-page":"14","article-title":"Double-blind, placebo-controlled trial to evaluate the effectiveness of Polypodium Leucotomos extract in the treatment of melasma in Asian skin: A pilot study","volume":"11","author":"Goh","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.065_bib104","first-page":"1198","article-title":"Oral polypodium leucotomos extract and its impact on visible light-induced pigmentation in human subjects","volume":"18","author":"Mohammad","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib105","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamadermatol.2013.4294","article-title":"A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma","volume":"149","author":"Ahmed","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib106","first-page":"351","article-title":"Topical tacrolimus and oral dapsone combination regimen in lichen Planus Pigmentosus","volume":"13","author":"Verma","year":"2015","journal-title":"Skinmed"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib107","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-4632.2004.01984.x","article-title":"Erythema dyschromicum perstans: response to dapsone therapy","volume":"43","author":"Bahadir","year":"2004","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.065_bib108","first-page":"796","article-title":"Erythema dyschromicum perstans: response to dapsone therapy","volume":"37","author":"Kontochristopoulos","year":"1998","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.065_bib109","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1111\/jdv.13454","article-title":"Lichen planus pigmentosus: a retrospective clinico-epidemiologic study with emphasis on the rare follicular variant","volume":"30","author":"Sindhura","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib110","first-page":"282","article-title":"Pigmented and reticulated plaques of folds. A case of lichen planus pigmentosus-inversus?","volume":"12","author":"Mu\u00f1oz-P\u00e9rez","year":"2002","journal-title":"Eur J Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2021.12.065_bib111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjd.12536","article-title":"Facial hyperpigmentation: causes and treatment","volume":"169","author":"Vashi","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib112","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/jocd.12747","article-title":"The role of systemic treatments for skin lightening","volume":"17","author":"Juhasz","year":"2018","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib113","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/09546631003801619","article-title":"Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study","volume":"23","author":"Arjinpathana","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ijd.12999","article-title":"An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women","volume":"55","author":"Handog","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2021.12.065_bib115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CCID.S128339","article-title":"Glutathione and its antiaging and antimelanogenic effects","volume":"10","author":"Weschawalit","year":"2017","journal-title":"ClinCosmet Investig Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib116","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-4362.2001.01149.x","article-title":"Safety and efficacy of glycolic acid facial peel in Indian women with melasma","volume":"40","author":"Javaheri","year":"2001","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib117","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jocd.12260","article-title":"Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life","volume":"16","author":"Dayal","year":"2017","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib118","first-page":"372","article-title":"Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study","volume":"82","author":"Rendon","year":"2008","journal-title":"Cutis"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib119","first-page":"828","article-title":"The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study","volume":"28","author":"Sarkar","year":"2002","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib120","first-page":"756","article-title":"Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients","volume":"30","author":"Khunger","year":"2004","journal-title":"Dermatol Surg"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.065_bib121","first-page":"44","article-title":"A case of lichen Planus Pigmentosus with facial dyspigmentation responsive to combination therapy with chemical peels and topical retinoids","volume":"9","author":"Wolff","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2021.12.065_bib122","article-title":"Modified phenol peels for treatment-refractory hyperpigmentation of lichen planus pigmentosus: a retrospective clinico-dermoscopic analysis","volume":"20","author":"Sonthalia","year":"2019","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib123","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1524-4725.1997.tb00016.x","article-title":"Glycolic acid peels in the treatment of melasma among Asian women","volume":"23","author":"Lim","year":"1997","journal-title":"Dermatol Surg"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.065_bib124","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/archderm.138.12.1578","article-title":"Efficacy of glycolic acid peels in the treatment of melasma","volume":"138","author":"Hurley","year":"2002","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib125","first-page":"205","article-title":"Comparison of 30% salicylic acid with Jessner\u2019s solution for superficial chemical peeling in epidermal melasma","volume":"18","author":"Ejaz","year":"2008","journal-title":"J Coll Physicians Surg Pak"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.065_bib126","first-page":"1429","article-title":"Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner\u2019s solution chemical peels","volume":"32","author":"Sharquie","year":"2006","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1524-4725.1999.08145.x","article-title":"The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups","volume":"25","author":"Grimes","year":"1999","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib128","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1524-4725.2009.01103.x","article-title":"Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin","volume":"35","author":"Joshi","year":"2009","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib129","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jaad.2009.12.027","article-title":"A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women","volume":"63","author":"Kodali","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib130","first-page":"1032","article-title":"Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels","volume":"34","author":"Garg","year":"2008","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib131","first-page":"385","article-title":"Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma","volume":"30","author":"Nanda","year":"2004","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib132","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/DSS.0000000000001248","article-title":"Microneedling: a review and practical guide","volume":"44","author":"Alster","year":"2018","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib133","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1590\/abd1806-4841.20154748","article-title":"Microneedling in facial recalcitrant melasma: report of a series of 22 cases","volume":"90","author":"Lima Ede","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.065_bib134","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/jocd.13392","article-title":"Efficacy of microneedling plus topical 4% tranexamic acid solution vs 4% hydroquinone in the treatment of melasma: a single-blind randomized clinical trial","volume":"19","author":"Shamsi Meymandi","year":"2020","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/idoj.IDOJ_22_19","article-title":"A split face comparative study of safety and efficacy of microneedling with tranexamic acid versus microneedling with vitamin C in the treatment of melasma","volume":"11","author":"Menon","year":"2020","journal-title":"Indian Dermatol Online J"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib136","first-page":"626","article-title":"Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial","volume":"32","author":"Lee","year":"2006","journal-title":"Dermatol Surg"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib137","first-page":"36","article-title":"Intradermal tranexamic acid injection for the treatment of melasma: a pilot study with 48-week follow-up","volume":"13","author":"Lueangarun","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2021.12.065_bib138","first-page":"174","article-title":"Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma","volume":"1","author":"Steiner","year":"2009","journal-title":"Surg Cosmet Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib139","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-2077.118403","article-title":"A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma","volume":"6","author":"Budamakuntla","year":"2013","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1016\/j.jaad.2021.12.065_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9554.1000280","article-title":"Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: a comparative study","volume":"6","author":"Elfar","year":"2015","journal-title":"J Clin Exp Dermatol Res"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijwd.2017.01.004","article-title":"A review of laser and light therapy in melasma","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib142","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/DSS.0000000000000627","article-title":"Treatment of persistent facial postinflammatory hyperpigmentation with novel pulse-in-pulse mode intense pulsed light","volume":"42","author":"Park","year":"2016","journal-title":"Dermatol Surg"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib143","first-page":"1196","article-title":"Intense pulsed light for the treatment of refractory melasma in Asian persons","volume":"30","author":"Wang","year":"2004","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.29271\/jcpsp.2018.01.13","article-title":"Efficacy of intense pulse light therapy and tripple combination cream versus intense pulse light therapy and tripple combination cream alone in epidermal melasma treatment","volume":"28","author":"Shakeeb","year":"2018","journal-title":"J Coll Physicians Surg Pak"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/09546634.2015.1115812","article-title":"Topical tranexamic acid as an adjuvant treatment in melasma: side-by-side comparison clinical study","volume":"27","author":"Chung","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"7-8","key":"10.1016\/j.jaad.2021.12.065_bib146","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/14764172.2017.1418517","article-title":"Intense pulsed light is effective in treating postburn hyperpigmentation and telangiectasia in Chinese patients","volume":"20","author":"Li","year":"2018","journal-title":"J Cosmet Laser Ther"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib147","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00042728-200104000-00016","article-title":"Intense pulsed light for melanocytic lesions","volume":"27","author":"Moreno Arias","year":"2001","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib148","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1524-4725.2009.01383.x","article-title":"Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians","volume":"36","author":"Wattanakrai","year":"2010","journal-title":"Dermatol Surg"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib149","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1524-4725.2011.02001.x","article-title":"Efficacy and safety of Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser treatment of melasma","volume":"37","author":"Zhou","year":"2011","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/DSS.0000000000000653","article-title":"Clinical and histopathologic assessment of facial melasma after low-fluence Q-switched neodymium-doped yttrium aluminium garnet laser","volume":"42","author":"Hofbauer Parra","year":"2016","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib151","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/lsm.22757","article-title":"Successful and safe use of Q-switched lasers in the treatment of nevus of Ota in children with phototypes IV-VI","volume":"50","author":"Belkin","year":"2018","journal-title":"Lasers Surg Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib152","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2302\/kjm.46.188","article-title":"Evaluation of the effect of Q-switched ruby and Q-switched Nd-YAG laser irradiation on melanosomes in dermal melanocytosis","volume":"46","author":"Ogata","year":"1997","journal-title":"Keio J Med"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.065_bib153","first-page":"1001","article-title":"Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for acquired dermal melanocytosis","volume":"29","author":"Momosawa","year":"2003","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib154","first-page":"785","article-title":"Condition known as \u201cdark rings under the eyes\u201d in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser","volume":"32","author":"Watanabe","year":"2006","journal-title":"Dermatol Surg"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib155","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ijd.12085","article-title":"Treatment of nevus of Ota using low fluence Q-switched Nd:YAG laser","volume":"53","author":"Choi","year":"2014","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib156","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/09546634.2014.930409","article-title":"A retrospective analysis of the clinical efficacies of Q-switched alexandrite and Q-switched Nd:YAG lasers in the treatment of nevus of Ota in Korean patients [article]","volume":"26","author":"Choi","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.065_bib157","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1524-4725.2011.02092.x","article-title":"A retrospective study of q-switched alexandrite laser in treating nevus of ota","volume":"37","author":"Liu","year":"2011","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib158","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5021\/ad.2015.27.6.751","article-title":"Hypopigmentation induced by frequent low-fluence, large-spot-size QS Nd:YAG laser treatments","volume":"27","author":"Wong","year":"2015","journal-title":"Ann Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib159","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/lsm.20956","article-title":"A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma","volume":"42","author":"Chan","year":"2010","journal-title":"Lasers Surg Med"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.065_bib160","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s10103-018-2529-2","article-title":"A split-face study: comparison of picosecond alexandrite laser and Q-switched Nd:YAG laser in the treatment of melasma in Asians","volume":"33","author":"Lee","year":"2018","journal-title":"Lasers Med Sci"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib161","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/14764172.2017.1376098","article-title":"Effects of a fractional picosecond 1,064-nm laser for the treatment of dermal and mixed type melasma","volume":"20","author":"Chalermchai","year":"2018","journal-title":"J Cosmet Laser Ther"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.065_bib162","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/lsm.22735","article-title":"Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: a prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial","volume":"49","author":"Choi","year":"2017","journal-title":"Lasers Surg Med"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib163","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10103-020-02959-7","article-title":"Efficacy and safety of the picosecond 755-nm alexandrite laser for treatment of dermal pigmentation in Asians-a retrospective study","volume":"35","author":"Hu","year":"2020","journal-title":"Lasers Med Sci"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.065_bib164","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s10103-018-2560-3","article-title":"Q-switched double frequency Nd:YAG 532-nm nanosecond laser vs. double frequency Nd:YAG 532-nm picosecond laser for the treatment of solar lentigines in Asians","volume":"33","author":"Vachiramon","year":"2018","journal-title":"Lasers Med Sci"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/lsm.23316","article-title":"Comparative Effectiveness of 755-nm Picosecond Laser, 755- and 532-nm Nanosecond Lasers for Treatment of Caf\u00e9-au-Lait Macules (CALMs): a Randomized, Split-Lesion Clinical Trial","volume":"53","author":"Cen","year":"2021","journal-title":"Lasers Surg Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib166","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/archdermatol.2007.49","article-title":"Nevus of Ota successfully treated by fractional photothermolysis using a fractionated 1440-nm Nd:YAG laser","volume":"144","author":"Kouba","year":"2008","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.065_bib167","first-page":"1645","article-title":"The treatment of melasma with fractional photothermolysis: a pilot study","volume":"31","author":"Rokhsar","year":"2005","journal-title":"Dermatol Surg"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.065_bib168","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1524-4725.2009.01264.x","article-title":"Treatment of melasma in Asian skin using a fractional 1,550-nm laser: an open clinical study","volume":"35","author":"Lee","year":"2009","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib169","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2010.01.048","article-title":"Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study","volume":"64","author":"Kroon","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.065_bib170","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/lsm.20937","article-title":"Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study","volume":"42","author":"Wind","year":"2010","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib171","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/09546634.2011.565016","article-title":"Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study","volume":"23","author":"Kroon","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib172","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1468-3083.2011.04086.x","article-title":"Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm)","volume":"26","author":"Barysch","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib173","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3109\/09546634.2012.671911","article-title":"Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream","volume":"25","author":"Tourlaki","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib174","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1524-4725.2011.02178.x","article-title":"Treatment of melasma using a novel 1,927-nm fractional thulium fiber laser: a pilot study","volume":"38","author":"Polder","year":"2012","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.065_bib175","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/dsu.12176","article-title":"Split-face study using a 1,927-nm thulium fiber fractional laser to treat photoaging and melasma in Asian skin","volume":"39","author":"Lee","year":"2013","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib176","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/lsm.23173","article-title":"Treatment of Post-Inflammatory hyperpigmentation in Patients With Darker Skin Types Using a Low Energy 1,927 nm Non-Ablative Fractional Laser: a Retrospective Photographic Review Analysis","volume":"52","author":"Bae","year":"2020","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.065_bib177","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/lsm.23341","article-title":"Non-Ablative 1927 nm Fractional Thulium Fiber Laser: new, Promising Treatment Modality for Riehl\u2019s melanosis","volume":"53","author":"Kim","year":"2021","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2021.12.065_bib178","doi-asserted-by":"crossref","first-page":"5560386","DOI":"10.1155\/2021\/5560386","article-title":"1927 nm Thulium Laser Successfully Treats postinflammatory hyperpigmentation in Skin of Color","volume":"2021","author":"Alharbi","year":"2021","journal-title":"Dermatol Res Pract"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.065_bib179","first-page":"80","article-title":"Single-pass carbon dioxide versus multiple-pass Er:YAG laser skin resurfacing: a comparison of postoperative wound healing and side-effect rates","volume":"29","author":"Tanzi","year":"2003","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib180","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/lsm.22472","article-title":"Comparison of Q-switched Nd: YAG laser and fractional carbon dioxide laser for the treatment of solar lentigines in Asians","volume":"48","author":"Vachiramon","year":"2016","journal-title":"Lasers Surg Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.065_bib181","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1684\/ejd.2014.2513","article-title":"Laser treatment of solar lentigines on dorsum of hands: QS Ruby laser versus ablative CO2 fractional laser\u2014a randomized controlled trial","volume":"25","author":"Schoenewolf","year":"2015","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.065_bib182","first-page":"315","article-title":"The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study","volume":"9","author":"Trelles","year":"2010","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.065_bib183","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1524-4725.2009.01066.x","article-title":"Treatment of melasma using variable square pulse Er:YAG laser resurfacing","volume":"35","author":"Wanitphakdeedecha","year":"2009","journal-title":"Dermatol Surg"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2023.01.026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000}},{"DOI":"10.1016\/j.jaad.2023.04.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222002523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222002523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T20:22:31Z","timestamp":1712262151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222002523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":183,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0190962222002523"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.065","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.01.051","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(22)03189-9","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}